Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mircea Dediu"'
Autor:
Kenneth J. O'Byrne, Sergei M. Mikhailov, Helen J. Ross, Jack W. Singer, M. Smakal, Corey J. Langer, David F. Heigener, F. B. Oldham, Amy J. Eisenfeld, Larissa Sandalic, Mark A. Socinski, Tudor Ciuleanu, Krzysztof Leśniewski-Kmak, Mircea Dediu, Sergey Orlov
Publikováno v:
Journal of Thoracic Oncology. 3:623-630
Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience more toxicity, lower response rates, and shorter survival times than healthier patients treated with standard chemot
Autor:
Martin Reck, Matthew Joseph Gribbin, Mircea Dediu, David R. Spigel, Cristina L. Cebotaru, D. Ross Camidge, Robin Humphreys, Jimmie H. Harvey, Joachim von Pawel, N. L. Fox
Publikováno v:
Clinical lung cancer. 15(3)
Background This phase II study examined the efficacy of mapatumumab in combination with paclitaxel and carboplatin in patients with non–small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIB or stage IV advanced primary NSCLC
Autor:
Yong Jiang Hei, David R. Spigel, Keunchil Park, Rinat Galiulin, Natividad Martinez Banaclocha, Francesco Galimi, Oleksandr Sydorenko, Kaoru Kubota, Fiona H Blackhall, Robert Pirker, Giorgio V. Scagliotti, Ihor Vynnychenko, Mircea Dediu, Sheryl McCoy, Bin Yao, Yukito Ichinose, Tudor Ciuleanu, Zsolt Papai-Szekely
Purpose We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/paclitaxel improved overall survival (OS) vers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222c454ddddee6e7cb2f53863d935a4f
http://hdl.handle.net/2318/118283
http://hdl.handle.net/2318/118283
Autor:
Martin Reck, J. von Pawel, J. H. Harvey, E Kumm, Gilles Gallant, Mircea Dediu, C. L. Cebotaru, D. R. Camidge, N. L. Fox, David R. Spigel
Publikováno v:
Pneumologie. 65
Autor:
Andrew Arnold, Natasha B. Leighl, Tudor-Eliade Ciuleanu, Lesley Seymour, Mark D. Vincent, Frances A. Shepherd, David Fenton, Scott A. Laurie, Eliot Frymire, David Walde, I. Gauthier, Keyue Ding, Francis Laberge, Glenwood D. Goss, Christopher W. Lee, Mauro Zukin, Cheryl Ho, Jonathan Noble, Mircea Dediu, Peter M. Ellis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(1)
Purpose This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non–small-cell lung cancer (NSCLC). Patients and Methods Paclitaxel (200 mg/m2) and carboplatin (area
Autor:
Martin Reck, Tudor Ciuleanu, Coleman K. Obasaju, Nina Karaseva, Susan C. Guba, Shengyan Hong, Egbert F. Smit, Nick Thatcher, Kartik Konduri, Johnetta Blakely, Carla Visseren-Grul, Aleksandra Szczesna, Jacek Jassem, Paul Lorigan, Mircea Dediu, Axel Hanauske, Piotr Serwatowski, Mark A. Socinski
Publikováno v:
Socinski, MA, Smit, E F, Lorigan, P, Konduri, K, Reck, M, Szczesna, A, Blakely, J, Serwatowski, P, Karaseva, N A, Ciuleanu, T, Jassem, J, Dediu, M, Hong, SH, Visseren-Grul, C, Hanauske, A R, Obasaju, C K, Guba, S C & Thatcher, N 2009, ' Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer ', Journal of Clinical Oncology, vol. 27, no. 28, pp. 4787-4792 . https://doi.org/10.1200/JCO.2009.23.1548
Journal of Clinical Oncology, 27(28), 4787-4792. American Society of Clinical Oncology
Journal of Clinical Oncology, 27(28), 4787-4792. American Society of Clinical Oncology
Purpose Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was conducted to compare pemetrexed-carboplatin with etoposide-carboplatin for the trea
Autor:
Mircea Dediu
Publikováno v:
Lung Cancer. 36:217-218
As most of the oncologists dealing with small cell lung cancer (SCLC) are aware, no important progresses have been made within the last 20 years. Thus any advance in this field, especially concerning the chemotherapy regimens, should be regarded with
Autor:
Bin Yao, Ihor Vynnychenko, Fiona H Blackhall, N. Martinez Banaclocha, Y. J. Hei, Kaoru Kubota, G.V. Scagliotti, Oleksandr Sydorenko, Rinat Galiulin, R. Pirker, Zsolt Papai-Szekely, Yukito Ichinose, Mircea Dediu, K. Park, David R. Spigel, S. McCoy, Tudor-Eliade Ciuleanu
Publikováno v:
Journal of Clinical Oncology. 29:LBA7512-LBA7512
LBA7512 Background: This study evaluated whether motesanib (a selective oral inhibitor of VEGFR 1, 2 and 3; PDGFR and Kit) plus C/P improved overall survival (OS) compared with placebo + C/P in patients (pts) with nonsquamous NSCLC and in a subset of
Autor:
Gilles Gallant, D. R. Camidge, C. L. Cebotaru, N. L. Fox, E Kumm, J. von Pawel, Martin Reck, David R. Spigel, Mircea Dediu, J. H. Harvey
Publikováno v:
Journal of Clinical Oncology. 28:LBA7501-LBA7501
LBA7501 Background: Mapatumumab, a fully human agonist monoclonal antibody, targets and activates the death receptor TRAIL-R1. We conducted this randomized, controlled phase II trial to evaluate mapatumumab in combination with carboplatin and paclita
Autor:
Kenneth J. O'Byrne, M. Smakal, Corey J. Langer, Helen J. Ross, Mircea Dediu, Mark A. Socinski, Sergey Orlov, Aleksandra Szczesna
Publikováno v:
Lung Cancer. 49:S36